Form 8-K





Washington, D.C. 20549









Date of report (Date of earliest event reported): September 8, 2017



Codexis, Inc.

(Exact name of Registrant as Specified in its Charter)




Delaware   001-34705   71-0872999

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)

200 Penobscot Drive

Redwood City, CA 94063

(Address of Principal Executive Offices) (Zip Code)

(650) 421-8100

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 7.01 Regulation FD Disclosure.

On September 8, 2017, Codexis, Inc. (the “Company”) updated its corporate presentation (the “Corporate Presentation”) in connection with upcoming investor conferences. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference herein.

The information furnished in this Current Report on Form 8-K pursuant to Item 7.01 (including Exhibit 99.1) shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.






99.1    Corporate presentation of Codexis, Inc.   


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: September 8, 2017     CODEXIS, INC.
    By:   /s/ Gordon Sangster
    Name:   Gordon Sangster
    Title:   Senior Vice President and Chief Financial Officer



Exhibit No.


Exhibit Description

99.1    Corporate presentation of Codexis, Inc.   

Exhibit 99.1



Unlock the power of proteins TM Codexis Corporate Presentation September 2017 Nasdaq: CDXS 1


Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as ?may,? ?will,? ?should,? ?could,? ?would,? ?expects,? ?plans,? ?anticipates,? ?believes,? ?estimates,? ?projects,? ?predicts,? ?potential? or the negative of these terms, and similar expressions and comparable terminology intended to identify forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Other factors that could materially affect actual results, levels of activity, performance or achievement can be found in Codexis? Form 10-K for the period ended December 31, 2016 filed with the SEC on March 9, 2017 and Form 10-Q for the period ended June 30, 2017 filed with the SEC on August 9, 2017, including under the caption ?Risk Factors.? If any of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results, levels of activity, performance or achievement may vary significantly from what we projected. Our logo, ?Codexis,? ?CodeEvolver,? and other trademarks or service marks of Codexis, Inc. appearing in this presentation are the property of Codexis, Inc. This presentation contains additional trade names, trademarks and service marks of other companies. We do not intend our use or display of other companies? trade names, trademarks or service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies. 2


Welcome to the Protein Revolution 3


4 Digital Revolution genomics revolution digital revolution moore?s law genomics revolution estimated based on historical growth rate desktop computer laptop computer smart phone current capacity human genome project 1970 1980 2000 2010 2020


Complexity of Protein Structure—Function Relationships DNA Code Protein Structure Protein Function Infinitely Complex 5


The Protein Revolution ? Now Is the Time High DNA Protein Artificial Throughput Sequencing Revolution Intelligence Screening 6


Codexis ? Leading The Protein Revolution Company History Cumulative Investments Employees 15+ Years > $500m ~115 (65 in R&D) Patents & Applications Protein Project Pipeline * Growing Revenues > 900 worldwide 8 Proteins Commercialized $49m in 2016 + 25 Pre-Commercial (+44% y-o-y) 18% CAGR since 2014 * Codexis Pipeline Snapshot as of June 30, 2017 ( 7


CodeEvolver—Technological Tool of the Protein Revolution 8 high throughtput screening human expertise dna sequencing artificial intelligence function-driven mutations


Project speed driving codexis growth 40 scientists years per project 10 scientists years per project 2 scientists years per project future continued acceleration 2000 2005 2010 2015 9


A Growing List of Markets Served Pharmaceuticals food ingredients biotherapeutics future applications molecular diagnostics industrial enzymes 10


Productivity Improvements Reduce CAPEX SOLUTION Capacity constraints in existing supply chain From zero activity to commercial targets in <12 months 53% higher productivity 19% reduction in energy usage Expensive, toxic chemo-catalyst replaced No new factory needed ? [Codexis] helped avoid the cost of building a 2nd factory to meet the rising demand for Januvia.? Skip Volante, Merck VP R&D 11


CodeEvolver Licensing Creates Value Across Portfolio SOLUTION How to effectively leverage protein Licensed the CodeEvolver platform engineering to improve GSK?s portfolio? Deeply embedded the technology in house Applications from discovery to post launch Codexis earns front end and back end economics Partnership created around shared vision for proteins and mutual success of CodeEvolver ?We chose the Codexis platform after a thorough evaluation of the enzyme evolution landscape.? Doug Fuerst, GSK Technology Development Lead, Synthetic Biology 12


Rapid Product Launch Enabled by Cost-Efficient Process CHALLENGE SOLUTION Healthier food ingredient requires a Commercial targets met in 7 months lower cost process to enable the 20-fold catalyst stability improvement product launch 90+% reduction in catalyst system cost Enabled commercial production of the healthy ingredient < 2 years after 1st project discussion ?We view Codexis as an extension of our internal R&D programs at Tate & Lyle.? Michael Harrison, Tate & Lyle SVP, New Product Development 13


Therapeutic Enzyme to Treat Phenylketonuria (PKU) CHALLENGE SOLUTION Besides aggressive dietary control, First CodeEvolver drug discovery breakthrough no available treatment for > 80% of GI tract enables oral dosage Stability in convenient PKU patients > 50-fold stability improvement, in vitro In the USA ~1:15,000 Efficacy demonstrated in four preclinical models newborns have PKU, causing lifelong Human trials targeted to start in early 2018 neurocognitive symptoms ?Many individuals with PKU are eagerly awaiting new therapeutic options. CDX-6114 holds the potential of being an attractive treatment for PKU.? Dr. Gregory Enns, Professor of Pediatrics, Division of Medical Genetics, Stanford University Hospital 14


Improving Sensitivity and Precision in Molecular Diagnostics CHALLENGE SOLUTION Create more sensitive, fluid-based Codexis engineered enzymes for next gen diagnostic tests: earlier, less sequencing with greater sensitivity and precision invasive cancer detection Detection of very, very low concentrations of Detecting cancer has historically target DNA in blood required invasive tissue biopsy Dependable test results without tissue biopsies Ability to tailor enzyme performance to specific sample or test conditions Codexis? first product offerings to customers who are already using others? enzymes. Simpler sales process enables even faster time to Codexis product commercialization. 15


Codexis: Monetizing The Protein Revolution Proven Revenue Generation & Partnering Approaches Engineer proteins sell proteins major partnerships biotherapeutics discovery 16


Growing R&D Revenues * Excludes CodeEvolver milestone revenue and the one-time 4Q?15 royalty settlement but includes amortized upfront revenues from CodeEvolver platform licensees. 17


Growing Product Revenue and Expanding Margins * 2017 Guidance Range Provided on August 9, 2017 18


Growing list of major partnerships driving growth partner type of partnering deal gsk merck t&l (march 17 deal) 2h?17 new partner another new major partner code evolver platform major product (food ingredient) target 2014 2015 2016 2017 2018+ 19


Codexis Biotherapeutics Pipeline PKU CDX-6114 Drug Target 1 (DT1) DT2 DT3 DT4 Step-out opportunities from monetizing biotherapeutics pipeline 20


Consistently Growing Total Revenues * 2017 Guidance Range Provided on August 9, 2017 21


Codexis Investment Summary Protein Revolution Leadership $500+ million invested over 15+ years Every project adds to CodeEvolver knowledge base and enhances value Deep Relationships with Industry Leaders Multiple revenue streams validate the CodeEvolver technology platform Further upside in molecular diagnostics, therapeutics, and new verticals Strong Financial Momentum Forecasted 2017 revenues of $50-$53 million Includes >$25 million product sales, more than doubled over past 2 years Clean, Sufficient Balance Sheet $28.8 million as of June 30, 2017 22


Contact Us John Nicols President & Chief Executive Officer (650) 421-2388 Gordon Sangster Corporate Headquarters Senior Vice President & Chief Financial Officer 200 Penobscot Drive Redwood City, CA 94063 (650) 421-8115 USA Jody Cain Lippert Heilshorn & Associates Codexis Investor Relations Partner (310) 691-7100 23